HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

• Status: Not yet recruiting
• Trial end date: 2025-12-30

Summary

The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Calcium; Fluorouracil; Gemcitabine; Leucovorin; Levoleucovorin; Oxaliplatin; Paclitaxel